Impact on Follow-up Strategies in Patients with Primary Sclerosing Cholangitis

Background & Aims: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow-up strategies in PSC with the hypothesis that regular imaging improves survival.

Methods: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or last clinical follow-up alive. The primary endpoint was all-cause mortality.

Results: A broad variety of different follow-up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow-up, was 0.61 (0.47-0.80) for scheduled imaging with and without ERCP; 0.64 (0.48-0.86) for US/MRI and 0.53 (0.37-0.75) for follow-up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high-grade dysplasia as a time-dependent covariate, HR 0.57 (0.44-0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow-up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed.

Conclusions: Follow-up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures.

Citing Articles

Primary sclerosing cholangitis.

Manns M, Bergquist A, Karlsen T, Levy C, Muir A, Ponsioen C Nat Rev Dis Primers. 2025; 11(1):17.

PMID: 40082445 DOI: 10.1038/s41572-025-00600-x.

The Constellation of Risk Factors and Paraneoplastic Syndromes in Cholangiocarcinoma: Integrating the Endocrine Panel Amid Tumour-Related Biology (A Narrative Review).

Ciobica M, Sandulescu B, Chicea L, Iordache M, Groseanu M, Carsote M Biology (Basel). 2024; 13(9).

PMID: 39336089 PMC: 11429066. DOI: 10.3390/biology13090662.

Surrogate markers of bile duct disease progression in primary sclerosing cholangitis - A prospective study with repeated ERCP examinations.

Farkkila M, Aberg F, Alfthan H, Jokelainen K, Puustinen L, Kautiainen H JHEP Rep. 2024; 6(10):101161.

PMID: 39290402 PMC: 11405802. DOI: 10.1016/j.jhepr.2024.101161.

Long-term impact of scheduled regular endoscopic interventions for patients with primary sclerosing cholangitis.

Ozdirik B, Veltzke-Schlieker W, Nicklaus J, Berger H, Schmidt D, Leonhardt S Hepatol Commun. 2024; 8(9).

PMID: 39225697 PMC: 11371311. DOI: 10.1097/HC9.0000000000000494.

Quantitative Magnetic Resonance Cholangiopancreatography Scoring and Its Predictive Value for Outcomes in Adults with Primary Sclerosing Cholangitis.

Mandea M, Iacob S, Grasu M, Anghel C, Iacob R, Ghioca M J Clin Med. 2024; 13(15).

PMID: 39124814 PMC: 11312640. DOI: 10.3390/jcm13154548.

References

Ali A, Tabibian J, Nasser-Ghodsi N, Lennon R, DeLeon T, Borad M . Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. Hepatology. 2017; 67(6):2338-2351. DOI: 10.1002/hep.29730. View

Chapman R, Fevery J, Kalloo A, Nagorney D, Boberg K, Shneider B . Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010; 51(2):660-78. DOI: 10.1002/hep.23294. View

von Seth E, Ouchterlony H, Dobra K, Hjerpe A, Arnelo U, Haas S . Diagnostic performance of a stepwise cytological algorithm for biliary malignancy in primary sclerosing cholangitis. Liver Int. 2018; 39(2):382-388. DOI: 10.1111/liv.14007. View

von Seth E, Arnelo U, Enochsson L, Bergquist A . Primary sclerosing cholangitis increases the risk for pancreatitis after endoscopic retrograde cholangiopancreatography. Liver Int. 2014; 35(1):254-62. DOI: 10.1111/liv.12640. View

Boyd S, Mustonen H, Tenca A, Jokelainen K, Arola J, Farkkila M . Surveillance of primary sclerosing cholangitis with ERC and brush cytology: risk factors for cholangiocarcinoma. Scand J Gastroenterol. 2016; 52(2):242-249. DOI: 10.1080/00365521.2016.1250281. View

Weismuller T, Trivedi P, Bergquist A, Imam M, Lenzen H, Ponsioen C . Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology. 2017; 152(8):1975-1984.e8. PMC: 5546611. DOI: 10.1053/j.gastro.2017.02.038. View

Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A . Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002; 36(3):321-7. DOI: 10.1016/s0168-8278(01)00288-4. View

Aabakken L, Karlsen T, Albert J, Arvanitakis M, Chazouilleres O, Dumonceau J . Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy. 2017; 49(6):588-608. DOI: 10.1055/s-0043-107029. View

Lewis J, Talwalkar J, Rosen C, Smyrk T, Abraham S . Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma. Am J Surg Pathol. 2009; 34(1):27-34. DOI: 10.1097/PAS.0b013e3181bc96f9. View

10.

Charatcharoenwitthaya P, Enders F, Halling K, Lindor K . Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology. 2008; 48(4):1106-17. DOI: 10.1002/hep.22441. View

11.

Razumilava N, Gores G, Lindor K . Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011; 54(5):1842-52. PMC: 3205332. DOI: 10.1002/hep.24570. View

12.

Singhi A, Nikiforova M, Chennat J, Papachristou G, Khalid A, Rabinovitz M . Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures. Gut. 2019; 69(1):52-61. PMC: 6943248. DOI: 10.1136/gutjnl-2018-317817. View

13.

Han S, Kahaleh M, Sharaiha R, Tarnasky P, Kedia P, Slivka A . Probe-based confocal laser endomicroscopy in the evaluation of dominant strictures in patients with primary sclerosing cholangitis: results of a U.S. multicenter prospective trial. Gastrointest Endosc. 2021; 94(3):569-576.e1. DOI: 10.1016/j.gie.2021.03.027. View

14.

Nguyen N, Schoeman M, Ruszkiewicz A . Clinical utility of EUS before cholangioscopy in the evaluation of difficult biliary strictures. Gastrointest Endosc. 2013; 78(6):868-874. DOI: 10.1016/j.gie.2013.05.020. View

15.

Trivedi P, Crothers H, Mytton J, Bosch S, Iqbal T, Ferguson J . Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age. Gastroenterology. 2020; 159(3):915-928. DOI: 10.1053/j.gastro.2020.05.049. View

16.

Levy C, Lymp J, Angulo P, Gores G, LaRusso N, Lindor K . The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005; 50(9):1734-40. DOI: 10.1007/s10620-005-2927-8. View

17.

Wannhoff A, Rupp C, Friedrich K, Brune M, Knierim J, Flechtenmacher C . Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis. Clin Gastroenterol Hepatol. 2015; 13(13):2372-9. DOI: 10.1016/j.cgh.2015.07.014. View

18.

. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009; 51(2):237-67. DOI: 10.1016/j.jhep.2009.04.009. View

19.

Chapman M, Thorburn D, Hirschfield G, Webster G, Rushbrook S, Alexander G . British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis. Gut. 2019; 68(8):1356-1378. PMC: 6691863. DOI: 10.1136/gutjnl-2018-317993. View

20.

Bowlus C, Lim J, Lindor K . AGA Clinical Practice Update on Surveillance for Hepatobiliary Cancers in Patients With Primary Sclerosing Cholangitis: Expert Review. Clin Gastroenterol Hepatol. 2019; 17(12):2416-2422. DOI: 10.1016/j.cgh.2019.07.011. View